Baxa Features Exacta-Med® And PhaSeal® Systems For Safe Handling And Administration Of Fluid Drugs At Interphex 2005
Baxa Corporation will present its proprietary systems designed to enhance the safety and efficiency of fluid medication handling and delivery at the 26th annual Interphex Conference and Exhibition -- April 26 – 28 at the Jacob K. Javits Center in New York. Its PhaSeal and Exacta-Med products offer added value to packaged pharmaceuticals as part of a complete drug delivery system.
New York, NY (PRWEB) April 26, 2005 -- At the 26th annual Interphex
Conference and Exhibition, Baxa Corporation will present its proprietary systems
designed to enhance the safety and efficiency of fluid medication handling and
delivery. Its PhaSeal and Exacta-Med products offer added value to packaged
pharmaceuticals as part of a complete drug delivery system.
PhaSeal, the
only closed system for safe handling of antineoplastic and other hazardous
drugs, has been documented to reduce or eliminate human exposure to toxic
hazards in the workplace. The system allows healthcare workers to reconstitute,
transport, and administer hazardous drugs without risk of environmental
contamination. Closed systems are recommended by the National Institute for
Occupational Safety and Health (NIOSH) in its 2004 Alert to prevent occupational
and environmental exposure to hazardous drugs.
Exacta-Med Dispensers
provide safe oral and enteral medication delivery by eliminating the risk of
wrong-route administration. The system’s non-luer components cannot actuate a
needleless valve or connect to a hypodermic needle or fitting. Oral dispensers
are recommended by the Institute for Safe Medication Practices (ISMP) to reduce
the opportunity for med errors.
Interphex 2005, held April 26 – 28 at the
Jacob K. Javits Center in New York, brings together global companies serving the
pharmaceutical and biotechnical industries. This year’s exhibition is paired
with an application-oriented conference to help industry professionals develop
critical on-the-job skills.
“Interphex offers Baxa an opportunity to find
pharmaceutical partners,” states Joyce Federer, Director of OEM Sales, “Our goal
is to help other manufacturers create greater product value for mature products,
improve the safety of their medication delivery, or to improve the outcomes of
their clinical trials. Baxa, with thirty years’ experience in the hospital
pharmacy, is in a unique position to offer regulatory expertise and market
knowledge that can assist other companies in the development of specialized
products for drug delivery applications, or to add value through improved
patient safety and compliance.”
Founded in 1975, Baxa Corporation built
its reputation by designing niche products that provide solutions for the
transfer, delivery, packaging and administration of fluid medications in
hospital pharmacy and alternate-site settings worldwide. The company is
certified to the quality standards for ISO 13485 and EN46001.
About Baxa
Corporation
Celebrating 30 years of business in 2005, Baxa Corporation is a
Denver-based manufacturer of medical devices and systems for preparing,
handling, packaging, and administering liquid medications. The company
manufactures and markets a wide range of healthcare products for use in
hospitals, critical care units and alternate-site pharmacies. Privately held,
Baxa Corporation has subsidiaries and sales offices in Canada, the United
Kingdom; Denmark, and Germany; and distribution partners worldwide. Further
information is available at http://www.baxa.com.
About Interphex 2005
The
world’s largest and most comprehensive pharmaceutical conference and exhibition
is held annually at the Jacob K. Javits Center. Sponsored by Reed Exhibitions,
the meeting features 1,000 global exhibitors in the areas of
PharmaManufacturing, PharmaSourcing & Services, PharmaIT and
PharmaFacilities. Further information is available at http://www.interphex.com.
Click the following link to
view a presentation by Jim Jorgenson "Using a Closed System Device to Reduce
Occupational Exposure to Hazardous Drugs." Jorgenson is Director of Pharmacy for
the Huntsman Cancer Institute and Associate Dean for Professional Affairs at the
University of Utah:
http://www.isips.org/presentations/PhaSeal/player.html
Contacts:
Marian
Robinson
Vice President, Marketing
Baxa Corporation
800.567.2292 ext.
2157
or 303.617.2157
Email: e-mail protected from spam
bots
Maggie Chamberlin Holben, APR
Absolutely Public
Relations
303.984.9801
or 303.669.3558
Email: e-mail protected from
spam bots
# # #
Source : http://www.prweb.com/releases/2005/4/prweb232561.htm